First Chimeric Antigen Receptor T-Cell Therapy Approved

On August 30, the U.S. Food and Drug Administration approved tisagenlecleucel for pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL). That approval came after positive clinical trial results with chimeric antigen receptor (CAR) T-cell therapies last spring and summer increased dramatically.

http://ift.tt/2ipf75o